Introduction {#sec1}
============

Prostate cancer is the most common non-cutaneous cancer and the second leading cause of cancer related mortalities among American men.[@bib1] The recent and exciting identification of germline *HOXB13 (G84E)* mutations within a subset of familial prostate cancers by Isaacs and Cooney in 2012 highlights a novel set of genes and transcriptional signaling pathways to understand prostate tumor etiology and develop new treatment modalities to combat prostate tumor initiation and progression.[@bib2] Prior to this discovery, much was already known regarding the expression and function of *HOX* genes, and their co-factors, in development and cancer. However, there remain significant gaps in our current understanding of HOX biology in prostate development and disease.

The role of *HOX* genes in organismal development {#sec2}
=================================================

HOX proteins are highly evolutionarily conserved, homeodomain-containing transcription factors best known for their roles in body axis patterning and tissue differentiation of developing embryos.[@bib3], [@bib4] Furthermore, recent studies have shown HOX proteins not only have a role development and organogenesis, but they also contribute to the control of several other processes into adulthood such as cell proliferation, cell cycle, apoptosis, cell differentiation, and cell migration.[@bib3], [@bib5], [@bib6] In humans, the 39 HOX proteins are divided into four *HOX* gene clusters: A, B, C, and D located on chromosomes 7p15, 17q21.2, 12q13, and 2q31 respectively.[@bib7] Each cluster is comprised of paralogous genes 1--13 whose 3′ to 5′ organization and expression both follow a pattern of spatial and temporal co-linearity with development, although not every paralog is present in each cluster. The 3′ *HOX* genes are most highly expressed in the anterior body regions that arise early in development, while the 5′ *HOX* genes encode more posterior regions that form later in development. The term, "HOX Code," refers to the phenomenon where tissue specificity is determined by nested and partially overlapping expression of several *HOX* genes in a given region. The most 5′ *HOX* gene expressed in a given tissue, however, has dominance in determining a specific tissues\' identity compared to the more 3′ *HOX* gene that may be co-expressed.[@bib8] For example, while 36 of the 39 *HOX* genes are expressed at a detectable level by qRT-PCR in a gross sample of human prostate tissue, it is the 5′ *HOX* genes like *HOXA13* and *HOXB13* that are most highly expressed and most significantly confer prostatic identity.[@bib9] Several excellent and in-depth reviews have already been published on the general role of *HOX* genes in development and cancer.[@bib3], [@bib6], [@bib10], [@bib11], [@bib12]

*HOX* expression in male reproductive system {#sec3}
============================================

The male reproductive tract is derived from two main developmental structures: the Wolffian (mesonephric) duct, which gives rise to the testis, epididymis, vas deferens, and seminal vesicle; and the urogenital sinus (UGS), which gives rise to the prostate, bulbourethral (Cowper\'s) glad, bladder, and urethra.[@bib13] Given that the reproductive tract is one of the most posterior systems in the body, expression of primarily posterior *HOX* genes like those in paralog groups 9--13 is most commonly observed ([Fig. 1](#fig1){ref-type="fig"}A and B).[@bib4], [@bib8], [@bib14] However, several 3′ *HOX* genes are also expressed in the testis and are thought to have critical roles in spermatogenesis rather than in testis function ([Fig. 1](#fig1){ref-type="fig"}A).[@bib14]Fig. 1**Expression patterns of HOX genes in the rodent male reproductive system**. **A)** Depiction of the spatially-restricted pattern of HOX expression in rodent reproductive structures throughout development. Data is compiled from references \#4, 8, 16, 18--20, and 73--76. **B)** Representation of lobe specific, posterior HOX gene expression in the adult rat prostate and seminal vesicle, determined by real time RT-PCR in Huang et al 2007 (reference \#4). The seminal vesicle (SV), coagulating gland (CG), ventral prostate (VP), lateral prostate (LP), and dorsal prostate (DP) each have a unique signature of posterior HOX gene expression levels that likely aids in conferring identity. Notably, HOXB13 shows the largest variation in expression between lobes of the prostate and is restricted to urogenital sinus (UGS) derived structures; thus it is absent in the SV. It should also be noted that for studies done in mice, Podlasek et al. demonstrated a different relative expression pattern of HOXA10, HOXA13, and HOXD13 between lobes of the prostate compared to the rat. In their studies, they found that the lowest prostatic expression of HOXA10 was in the CG, rather than VP (reference \#19). Additionally, highest expression of HOXD13 was in the SV rather than DP, and followed in order of decreasing expression by the VP, CG, and DP (reference \#16). HOXA13 followed a similar pattern as HOXD13, although the CG does not seem to have been analyzed for HOXA13 expression (reference \#20). The drawing of the rodent prostate is adapted from reference \#77.Fig. 1

Many of the *Hox* paralogs have redundant and overlapping functions rendering the identification of specific roles for each gene complicated; however, some insight has been gained by observing phenotypes of various *Hox* gene knockout rodents. For example, while homozygous loss of *Hoxa13* (*Hoxa13*^−/−^) is considered embryonic lethal due to the perceived role of *Hoxa13* in umbilical artery maintenance, examination of *Hoxa13*^−/−^ fetuses shows severe hypoplasia of the urogenital sinus and arrested or delayed rostral-to-caudal progression of Müllerian ducts.[@bib15] Additionally, *Hoxd13* deficient mice (*Hoxd13*^−/−^) reveal diminished folding in the seminal vesicle stromal sheath, reduced ductal branching and size of the dorsal and ventral prostate lobes, and agenesis of the bulbourethral gland.[@bib16] Furthermore, compound homozygous mutants (double *Hoxa13*^−/−^ and *Hoxd13*^−/−^) fetuses have undetectable development of the genital tubercle, nor any distinct hindgut and urogenital sinus, among other deformities.[@bib15] In contrast, mice expressing *Hoxb13* with a loss-of-function mutation in the homeodomain show no gross morphological defects, but rather have prostate ventral lobe-specific defects in histology and secretory function.[@bib17] Histologically, ventral lobe epithelium from *Hoxb13* mutant mice are composed of simple cuboidal rather than the tall columnar luminal cells that make up healthy prostate epithelium, and are also devoid of the ventral-specific secretory proteins p12 and p25.[@bib17] For a thorough review of reproductive system phenotypes observed with various 5′ *Hox* gene knockouts, please refer to "Homeobox genes and the male reproductive system" by Rao and Wilkinson.[@bib18]

In addition to the spatial and temporal patterns of *Hox* gene expression there is also clear species specificity to the pattern. This is especially well demonstrated when noting the *Hox* patterns of the prostate in developing mice, rats, and adult humans; however, it should be noted that there is very little data regarding *HOX* expression in the developing embryonic human prostate. While at a glance, many of the same *HOX* genes are expressed in all three of these species, the timing, location, and amount of expression can all vary. In murine prostates, Bushman et al found that *Hoxa10* expression peaked at embryonic day 19 (E19) and decreased rapidly after birth to near undetectable levels by post-natal day 5 (P5).[@bib19] They also showed that *Hoxa13* and *Hoxd13* expression both peaked around E15 and steadily diminished from there into adulthood; spatially, both *Hoxa13* and *Hoxd13* had epididymal expression which peaked in the seminal vesicle.[@bib20] This observation of *Hoxa13* and *Hoxd13* expression appears to contrast to the work of Prins et al within the rat prostate demonstrating a postnatal increase in expression that is maintained into adulthood for all three of the previously mentioned genes.[@bib4] They also demonstrated that *Hoxa13* and *Hoxd13* peaked in expression within the dorsal prostate rather than seminal vesicle, and also had a clear anterior boundary at the epididymis.[@bib4] Furthermore, in the rat prostate, Prins et al demonstrated *Hoxd13* to be the highest expressing *Hox* gene in each lobe, followed closely by *Hoxa13* and *Hoxb13*, and lastly *Hoxa9*, *Hoxa10*, and *Hoxa11* each with approximately 10-fold less RNA expression compared to the *Hox13* levels.[@bib4] In a study evaluating *HOX* gene expression in a variety of normal adult human organs including prostate, *HOXA9, HOXA11, HOXA13, HOXB13*, and *HOXD9* were all identified as the highest expressing *HOX* genes with *HOXA10* and notably *HOXD13* each at a 10-fold lower expression level in the prostate compared to *HOXA13* and *HOXB13*.[@bib9] In summary, as expected the 5′ *HOX* genes (*Hoxa*-*d13*) clearly appear to be critical for prostate and GU development, but the timing and location across species is distinct and should be taken into consideration when using animal model systems for HOX biology.

The germline *HOXB13-G84E* mutation and prostate cancer {#sec4}
=======================================================

The identification of the germline *HOXB13(G84E)* mutation by Ewing et al within a subset of familial prostate cancers in 2012 brought HOXB13, the genes regulated by HOXB13, and HOX-protein co-factors, into the spotlight of prostate cancer research.[@bib2] This discovery highlighted a novel transcriptional regulation pathway that has a key role in prostate development and tumor etiology.[@bib2] Patients with the mutation, which substitutes a glutamic acid for glycine at the second position of codon 84, have significantly higher odds for developing prostate cancer than men without the mutation.[@bib2] The G84E mutation occurs within the MEIS interaction domain of *HOXB13*, emphasizing the importance of MEIS-HOX protein interactions in prostate cancer ([Fig. 2](#fig2){ref-type="fig"}). Since the initial study, several additional studies have validated the G84E mutation as associated with increased prostate cancer risk ([Table 1](#tbl1){ref-type="table"}). It is important to note that the majority of these studies were conducted on Caucasian men of European ancestry, with only 5 of these 22 studies included multiple ethnicities in the study group. In a study conducted by the International Consortium for Prostate Cancer Genetics (ICPCG), they observed a geographical frequency gradient of the G84E mutation across the European continent, with a higher mutation frequency in Nordic countries.[@bib21] While multiple studies have corroborated that the G84E mutation is associated with increased prostate cancer risk, the data on the association of G84E with other clinically relevant variables has been mixed. Regarding age of diagnosis, the G84E mutation has been shown to be significantly associated with younger age of diagnosis in the majority of studies,[@bib2], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27] with other studies reporting no difference in age of diagnosis.[@bib28] A similar pattern has emerged regarding a positive family history of prostate cancer, with all studies reporting a significantly higher odds of the G84E mutation being present in patients with a positive family history or hereditary prostate cancer. In the context of G84E and a potential role in the initiation of more aggressive prostate tumors, Storjberg et al determined that patients carrying the G84E mutation had a significantly higher PSA at diagnosis, higher Gleason score, and a higher likelihood of positive surgical margins at time of radical prostatectomy than non-carriers, implying that the G84E mutation maybe associated with more aggressive prostate cancers.[@bib29] However, further analyses are necessary to determine whether mutation of *HOXB13* is associated with poor-prognosis prostate tumors. Genetic studies of prostate tumors, however, have documented that in sporadic prostate cancer, *HOXB13* is more likely to be amplified but not mutated.[@bib30], [@bib31], [@bib32] In summary, the presence of G84E mutation clearly impacts prostate cancer initiation, but data thus far has not strongly implicated the presence of the mutation in contributing to cancer progression and metastasis.Fig. 2**Genomic location, domains, and known mutations of human HOXB13**. Since the original report of somatic *HOXB13(G84E)* mutations in a subset of familial cancer, more hereditary mutations conferring increased risk of prostate cancer have been identified (reference \#2). The *HOXB13* gene is located on human Chromosome 17q21.32 at the 5′ end of the 17q21-22 HOXB cluster, and consists of two exons and three known functional domains (accession number NC_000017/11 and ProtID Q92826). The HOXB13 transcript is 3987 base-pairs (b.p.) long, and Exons 1 and 2 are positioned at 157--757b.p. and 1707--1960b.p, respectively. The regions in beige indicates the untranslated regions (UTR), while the regions in brown indicate coding regions (CDR). The HOXB13 protein is 284 amino acids in length and contains two MEIS-interacting domains (amino acids 80--91 and 136--146) and a single DNA-binding homeobox domain (amino acids 217--275). The two Meis-interaction domains were functionally defined by Williams et al (reference \#78 and 79), and the homeodomain was functionally defined in Zeltzer et al (reference \#80). Clusters of mutations can be seen within or nearby the two MEIS-interacting domains and the homeodomain.Fig. 2Table 1HoxB13(G84E) mutations in prostate cancer.Table 1AuthorPMIDStudy yearPatient populationAge of PrCa Onset G84E Carrier^h^Study type^i^Genotyping assaySample \#Cancer casesNon-cancer controlsOR (95% CI)*P*-valueCancerNon-cancerMutationNon-mutationMutationNon-mutationAkbari227814342012Multiple ethnicities, multiple countries59.4HBSanger sequencing18532225101843222235.8 (1.3--26.5)0.01Albitar F258740032015USA, CaucasianNRHBSanger sequencing232110223011090.95 (0.09--10.6)0.97Beebe-Dimmer^a^261084612015Mayo Clinic Biobank, Primarily CaucasianNRHBTaq-Man4272181923134358751.99 (1.37--2.90)\<0.0001Breyer227147382012Multiple countries, multiple ethnicities53.4HBTaq-Man9289302090829287.9 (1.8--34.5)0.0062Chen233932222013Multiple countries, multiple ethnicitiesNRHBiPLEX MassARRAY2038877137013186RR = 2.45 (1.48--4.07)0.01Ewing\*222362242012USA, Caucasian52.6HBTaq-Man508326627250114265820.1 (3.5--803.3)8.50E-07Gudmundsson^a^231040052012Chicago-SPORE, Caucasian58.3HBIllumina SNP Chips19881260111971512551.40 (0.49--4.04)5.30E-01Gudmundsson^b^231040052012Iceland, Caucasian66.2HBIllumina SNP Chips45375444413452444544003.55 (1.91--6.60)1.00E-04Gudmundsson^c^231040052012Netherlands, Caucasian63.9HB/PBIllumina SNP Chips15201916231497419127.34 (2.53--21.3)3.90E-10Gudmundsson^d^231040052012Spain, CaucasianNRHBIllumina SNP Chips71716921716016927.09 (0.29--174.2)2.30E-01Gudmundsson^e^231040052012United Kingdom, Caucasian61.7HBIllumina SNP Chips561182565051182421.67 (2.60--180.4)4.40E-03Gudmundsson^f^231040052012Romanian, Caucasian69.4HBIllumina SNP Chips722857172118561.19 (0.07--19.0)9.31E-01Karlsson^a^228416742014Swedish, CaucasianNRPBiPLEX MassARRAY2805170913026752416853.4 (2.2--5.4)6.40E-10Karlsson^b^228416742014Swedish, Stockholm-1 group, CaucasianNRHBiPLEX MassARRAY209828809120073728433.5 (2.4--5.2)2.00E-11Kluzniak233348582013Polish, caucasian67.3PBTaq-Man35152604203495326014.96 (1.47--16.7)0.0097Kote-Jarai255959362015United Kingdom, CaucasianNRHBTaq-Man8652525213485182852242.94 (1.95--4.42)\<0.0001Laitinen232920822013Finnish, Caucasian\<=55HB/PBMultiple methods45719231604411288951.15 (0.77--1.74)0.47MacInnis234574532013Australian, caucasian52.7PBTaq-Man1384N/A191365N/AN/AIncidence: 16.4 (2.5--107.2)N/AStorebjerg267797682016Danish61.7HBSanger sequencing995162225970816145.12 (0.26--13.38)1.30E-05Stott-Miller231293852013USA, CaucasianNRPBTaq-Man14571442181439514373.6 (1.3--9.7)0.01Witte233969642013Multiple countries, multiple ethnicitiesNRFB/HBTaq-Man16451019201625310164.17 (1.24--14.1)0.02Xu230648732013Multiple countries, caucasian62.8FBiPLEX MassARRAY32611715417236812.01 (1.29--3.16)0.002[^1][^2][^3]

Other germline *HOXB13* mutations associated with prostate cancer risk {#sec5}
======================================================================

Since the discovery of the G84E mutation, there has been greater focus on identifying other novel germline mutations of *HOXB13* associated with increased prostate cancer risk. This is of particular importance for non-Caucasian populations, as the risk of prostate cancer associated with the G84E mutation has the highest frequency in European/Caucasian populations. Indeed, new mutations of *HOXB13* conferring increased prostate cancer risk have begun to be identified in non-Northern European ancestry. Notably, Lin et al identified the novel G135E mutation to be associated with increased prostate cancer risk in a population of Chinese men, and did not identify the presence of the G84E mutation.[@bib33] Similarly, Maia et al identified the A128D and F240L mutations in a population of Portuguese men to associated with prostate cancer risk.[@bib34] Ewing et al reported the identification of several rare missense variants of *HOXB13* (Y88D, L144P, G216C, R217C, and R229G, [Fig. 2](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}) during their initial study of G84E. Of these rare mutations, the R229G and G216C were identified in men with some African ancestry.[@bib2] Given the paucity of data, however, on non-G84E mutations of *HOXB13*, and the lack of study of prostate cancer risk mutations in non-Caucasian populations, continued efforts to identify novel risk mutations of *HOXB13* are necessary.Table 2Germline and somatic HoxB13 mutations in cancer.Table 2AuthorPMIDStudy yearCancer primaryPatient populationStudy type^f^Primary mutationGermline or somaticCancer casesNon-cancer controlsGenotyping assayOR (95% CI)*P* valueMutationsNon-mutationsMutationsNon-mutationsAkbari MR^a^230994372012BreastCanadian CaucasianHBG84EGermline218021924Taq-Man1.0 (0.09--11.3)0.98Akbari MR^b^230994372012BreastPolish CaucasianHBG84EGermline5222831834Taq-Man1.37 (0.33--5.75)0.67Akbari MR235412212013ColorectalCanadian, AustralianPBG84EGermline13268284585Taq-Man2.8 (1.2--6.7)0.02Beebe-Dimmer^b^261084612015BladderPrimary CaucasianHBG84EGermline3232055875Taq-Man1.99 (0.84--3.86)0.06Beebe-Dimmer^c^261084612015LeukemiaPrimary CaucasianHBG84EGermline323865875Taq-Man3.17 (1.35--6.03)0.01Beebe-Dimmer^d^261084612015SarcomaPrimary CaucasianHBG84EGermline1231235875Taq-Man1.48 (0.23--3.80)0.4Beebe-Dimmer^e^261084612015TestisPrimary CaucasianHBG84EGermline124495888Taq-Man2.31 (0.36--5.86)0.18Laitinen^a^232920822013BreastFinnish, CaucasianHB/PBG84EGermline16970161433Multiple methods1.48 (0.74--2.97)0.27Laitinen^b^232920822013ColorectalFinnish, CaucasianHB/PBG84EGermline74350459Multiple methods15.83 (0.90--277.95)0.06Lin227182782013ProstateChinesePBG135EGermline363901491iPLEX MassARRAY16.33 (0.84--316.54)0.065Maia261769442015ProstatePortugueseFBA128D/F248LGermline34590132AB 3500 Genetic Analyzer2.02 (0.10--39.3)0.64Ewing222362242012ProstateUSA, CaucasianHBY88DUnknown^g^N/AN/AN/AN/ATaq-ManN/AN/AEwing222362242012ProstateUSA, CaucasianHBL144PUnknown^h^N/AN/AN/AN/ATaq-ManN/AN/AEwing222362242012ProstateUSA, CaucasianHBG216CGermline190N/AN/ATaq-ManN/AN/AEwing222362242012ProstateUSA, CaucasianHBR229GGermline190N/AN/ATaq-ManN/AN/AXu230648732013ProstateMultiple countries, caucasianFBR217CGermline2642001902iPLEX MassARRAY1.48 (0.07--30.9)0.8[^4][^5][^6][^7]

The function of HOXB13 in the developing and adult prostate {#sec6}
===========================================================

HOXB13 is unique in the prostate because it is highly expressed into adulthood in multiple species, and yet it is the most differentially-expressed HOX protein when comparing between lobes of the rodent prostate, suggesting that it may have more important functions in determining prostatic identity and maintaining organ homeostasis in an adult.[@bib4], [@bib35] Within the normal adult human prostate, *HOXB13* is localized exclusively in prostate luminal epithelial cells.[@bib17], [@bib36] In rodent models, *Hoxb13* is most highly expressed in the ventral prostate lobe, has been shown to drive differentiation of prostate luminal epithelial cells, and is also required for the normal secretory function of the ventral prostate.[@bib4], [@bib17], [@bib35]

An important and somewhat controversial body of data pertains to the relationship between HOXB13 and the Androgen Receptor (AR). This pertains to both the regulation of *HOXB13* by AR and cooperation with AR signaling. *HOXB13* expression in the prostate is thought to be androgen-independent, as demonstrated by Bieberich et al whereby the steady state mRNA level of *HOXB13* in the murine prostate was undiminished 8 days after host castration.[@bib36] However, Prins et al observed increased *Hoxb13* expression in the rat prostatic ventral lobe upon administration of testosterone, and expression was decreased in the dorsal and lateral lobes upon castration.[@bib4] This apparent discrepancy could be accounted for by changes in prostatic cellularity in the context of hormone administration or depletion, since castration results in a significant reduction of *HOXB13*-positive luminal epithelial cells. In addition to regulation of *HOXB13* by androgen signaling, it has been shown that HOXB13 can act as a bivalent regulator of AR chromatin binding and function as either a growth-promoter or growth-suppressor in prostate cancer cells depending on the cellular context.[@bib37] For example, in androgen-sensitive prostate cancer cell lines such as LNCaP, increased HOXB13 activity can decrease levels of Cyclin D1 and lead to growth inhibition through reduction of pRb phosphorylation and stabilization of the pRB-E2F complex.[@bib5], [@bib6] Conversely, in castration-resistant prostate tumors, HOXB13 overexpression can inhibit p21 and thus act as an oncogene through subsequently promoting E2F activation and cell cycle progression.[@bib6] A final noteworthy observation of HOXB13 localization is that, in human radical prostatectomy samples, the nuclear/cytoplasmic ratios of HOXB13 are drastically reduced in prostatic intraepithelial neoplasia (PIN) and prostate cancer when compared to normal glands, indicating much higher cytoplasmic retention and thus lower amounts of functional HOXB13 in the nucleus of tumor cells.[@bib5] This suggests a potential mechanism of abrogating the growth-suppressive function of HOXB13 by cytosolic retention. Collectively, these observations highlight numerous important and interesting roles of HOXB13 in the prostate, but also underscore the need for additional mechanistic and functional studies to elucidate the molecular function of HOXB13 within the normal prostate and during prostate tumor initiation.

Germline *HOXB13(G84E)* in non-prostate tumors {#sec7}
==============================================

Given the strong relationship between the *HOXB13(G84E)* mutation and prostate cancer risk, as well as the importance of *HOXB13* in development and cancer, several studies have examined the role of *HOXB13* mutations in increasing the risk of other tumor types ([Table 2](#tbl2){ref-type="table"}). Results between the association of G84E and non-prostate cancer risk have been mixed. Notably, Akbari et al and Beebe-Dimmer et al showed that the G84E mutation was associated with a significantly increased risk of colorectal carcinoma and leukemia, respectively.[@bib38], [@bib39] However, Latinen et al showed no significant association between the G84E mutation and colorectal cancer risk, although their results did approach significance.[@bib27] The G84E mutation has also been investigated in breast, bladder, testis, and sarcoma, but results have not shown a significant association between the mutation and increased cancer risk among those cancers studied.[@bib38] However, it should be noted that a few of these studies approached near significance, and additional studies containing a larger sample size has the potential, in some instances, to establish a significant correlation between the G84E mutation and non-prostate cancer risk.

Deregulation of *HOXB13* in non-prostate tumors {#sec8}
===============================================

Despite its emerging role in prostate cancer, deregulation of *HOXB13* expression has been implicated in a variety of human cancers, functioning either as a tumor-promoting factor in some tumor types, or a tumor-repressing factor in others ([Table 2](#tbl2){ref-type="table"}). Surprisingly, aberrant expression of *HOXB13* has been documented in a variety of non-posterior axis cancers, including thyroid, breast, metastatic melanoma, and oral squamous cell ([Table 2](#tbl2){ref-type="table"}). In many instances, however, the functional significance of such expression has yet to be determined. In endometrial, ovarian, melanoma, and breast tumors, increased *HOXB13* expression appears to promote tumor progression.[@bib40], [@bib41], [@bib42] In endometrial tumors, Yamashita et al demonstrated *HOXB13* expression in tumor tissues and demonstrated that HOXB13 over-expression led to increased cellular invasion *in vitro.*[@bib40] In ovarian cancer, Miao et al demonstrated that over-expression of *HOXB13* in ovarian cancer cells resulted in increased cell proliferation and survival.[@bib41] In melanoma, Maeda et al showed that the expression levels of *HOXB13* were significantly higher in patients with metastatic melanoma compared to patients with a non-metastatic primary melanoma.[@bib43] In breast cancer, *HOXB13* expression is predictive of a poor clinical outcome in tamoxifen-treated breast cancers, indicating that increased *HOXB13* could have a prognostic role in breast cancer.[@bib44] Furthermore, ectopic expression of HOXB13 in MCF10A breast epithelial cells enhances motility and invasion *in vitro*, and *HOXB13* expression is increased in both pre-invasive and invasive primary breast cancer.[@bib44]

While the majority of the current literature demonstrates that *HOXB13* is generally over-expressed and tumor-promoting in most cancers, several studies support a role for *HOXB13* as a tumor-suppressor within other cancer contexts. Jung et al and Kanai et al showed that *HOXB13* expression is decreased in primary colorectal adenocarcinoma, and that over-expression of HOXB13 inhibits cell proliferation in colorectal cancer cell lines.[@bib44], [@bib45] Furthermore, Cantile et al showed a progressive decrease in HOXB13 nuclear expression in the transition from non-neoplastic thyroid to adenoma to different histologic types of thyroid cancer.[@bib46] In bladder cancer, Marra et al found that the loss of nuclear HOXB13 is implicated in shorter disease free survival in non-muscle invasive bladder cancer and decreased nuclear HOXB13 correlates with muscle invasion.[@bib47] Thus, it is clear that aberrant expression of HOXB13 plays a key role in the progression of many different cancer types, including both non-genitourinary and genitourinary cancers. Moreover, the context-dependent tumor promoting or repressing functions of HOXB13 further underscore key organ-specific roles of HOXB13 in cancer. Hence, it is the HOXB13-associated binding partners that provide specificity to DNA binding and subsequent gene targets who are the key mediators of HOX-associated tumor initiation and progression. Additional investigation into the function of HOXB13 and its binding partners across various tumors types is thus warranted.

HOX protein binding partners {#sec9}
============================

It has been a long-established paradox that HOX proteins achieve exquisite *in vivo* gene specificity to program development using simple "AT-rich" gene recognition motifs; such motifs are much too common across the genome to allow HOX proteins working alone to attain such gene specificity (expertly reviewed in Mann et al).[@bib48] To accomplish such specificity, HOX proteins rely on multiple co-factors to bind and specify transcriptional activity. The TALE (three amino acid loop extension) proteins are the predominant subtype of homeobox proteins that partner with HOX proteins and specify gene targeting and activity. This family of proteins includes the MEIS, PBX, PKNOX and TGIF homeobox proteins. While they contain the homologous DNA binding domain canonically found in homeobox genes, there are three unique characteristics of the TALE family. First, a three amino acid insertion in their homeodomains allows for cooperative binding to other transcription cofactors.[@bib49] It is this ability to create complexes that provide increased binding affinity of homeobox complexes to the DNA. Importantly, not every TALE protein group can bind to every other homeobox gene, increasing specificity of DNA binding depending on the combination of factors present in a complex.[@bib49] Second, the regions flanking the homeodomains of TALE proteins are highly conserved across species.[@bib50] Third and finally, unlike their spatiotemporally-restricted HOX relatives, TALE factors are more widely expressed across an organism.

While many TALE factors have been implicated in cancers, the recent discovery of the *HOXB13* mutations in hereditary prostate cancer to confer a risk for prostate cancer discussed above has sparked an interest in the MEIS proteins in particular.[@bib2] Many of the mutations within the *HOXB13* gene fall within the MEIS binding domain ([Fig. 2](#fig2){ref-type="fig"}). While it is clear, as discussed above, that *HOXB13* mutations are strongly associated with increased prostate cancer risk, there are significant gaps of knowledge regarding the mechanism of action of *HOXB13* mutations, and how co-factor modulations impact prostate cancer initiation.

The *MEIS* (murine ecotropic integration site) gene was implicated in cancer based upon the discovery that the *MEIS1* gene was the most common location for an ecotropic murine leukemia virus to integrate.[@bib51] When the virus integrated, higher expression was noted as the mice developed leukemia, and this was the first indication of *MEIS* as oncogenes in liquid tumors.[@bib51] MEIS proteins function as DNA-binding cofactors with the HOX and PBX families such that the cooperative binding increases DNA binding specificity.[@bib48], [@bib52], [@bib53], [@bib54] Our current understanding of MEIS-HOX interactions is that, upon DNA binding of the two, DNA-bound MEIS/HOX complexes recruit collaborator proteins to compile a multimeric protein complex at specific gene promoters.[@bib48] It should be noted, however, that TALE proteins have both HOX-dependent and HOX-independent functions and their role in development and disease likely extends beyond regulation of HOX protein DNA specificity.[@bib48], [@bib54]

Deregulation of MEIS proteins in cancer {#sec10}
=======================================

While little is known about the MEIS and PBX proteins in the context of prostate cancer, current understanding of functions in other cancer types may provide directions for future work. MEIS proteins have complicated and context-dependent roles in cancer initiation and progression. They are down-regulated in some cancer types, but overexpressed in others, making it unclear if *MEIS* genes are bona fide oncogenes or tumor suppressors genes. This phenomenon of fluidity between tumor suppression and oncogenesis is not unheard of; in fact, *HOX* genes display a very similar pattern, as discussed above.[@bib12]

The most well studied context for the role of MEIS, PBX and HOX proteins in cancer is leukemia, and specifically AML (Acute Myeloid Leukemia) and MLL (Mixed Lineage Leukemia). MEIS1 is required for normal adult bone marrow hematopoiesis, with deletion of *MEIS1* leading to stem cell exhaustion and an inability to self-renew.[@bib55] MEIS1 alone is not sufficient to transform hematopoietic cells however, as MEIS1 requires the cooperation of HOXA9 to accelerate HOX-induced leukemia.[@bib56] There is a common theme across many publications investigating MEIS in leukemia; MEIS proteins can mitigate differentiation while also increasing proliferation, a deadly and oncogenic combination. *MEIS1* and *HOXA9* are direct targets of the MLL fusion gene[@bib57] and MEIS1, in addition to the redundant contributions of PBX2 and 3, appears to be the rate-limiting step in the cell cycle progression of MLL leukemia stem cells.[@bib58] In fact, it was shown recently that PBX3 is crucial to help stabilize MEIS1 proteins, and that the dimerization of PBX3 and MEIS1 is required for HOX-induced leukemia.[@bib59] In myeloid leukemias, the full length MEIS1-A is able to stop differentiation through G-SCF and promotes proliferation.[@bib60]

The connection between MEIS1 and the cell cycle, as well as maintenance of a more primitive stem cell state across multiple cell types are likely mechanisms of action that lead to its deregulation in a range of pathological contexts. For example, MEIS1 slows adult and neonatal proliferation in cardiomyocytes by modulating the progression of the cell cycle.[@bib61] There are also multiple papers indicating a role for MEIS in Restless Leg Syndrome, and more information on MEIS′ role in this disease can be found in a 2014 review by Garcia-Borreguero et al[@bib62] Neuroblastoma displays *MEIS1* up-regulation in many cell lines and tumors.[@bib63] Neuroblastoma is also the context where many novel, and potentially functionally distinct, MEIS isoforms have been investigated.[@bib64] In neuroblastoma SJNB-8 cells, the exogenous expression of MEIS1-E, an isoform lacking a DNA binding domain, induces changes in cell growth proliferation apoptosis, cytoskeleton, long-distance gene regulation, morphogenesis, protein transport, and differentiation markers.[@bib64], [@bib65] This analysis, however, did not indicate the direction of change for many of these processes.[@bib65] MEIS2 is critical for neuroblastoma cell survival and proliferation by asserting control over M-phase of the cell cycle, again illustrating a cell cycle control function for MEIS in cancer cells.[@bib66] Lung adenocarcinomas, in particular those with LKB1 mutations, also show up-regulation of MEIS2, though investigation of the mechanism of action has not been elucidated.[@bib67] Thus, in numerous tumor sites, MEIS1 and MEIS2, and potential splice-variants of each, appear to function as promoters of cell cycle progression, and in some instances to maintain cancer cells in a less-differentiated state.

While the majority of cancer-related research into the MEIS and PBX transcription factors has been focused on their overexpression in leukemia, there are many pathological contexts where MEIS proteins appear to function as tumor suppressors. In fact, MEIS proteins can act as a tumor suppressor or oncogene even within a specific organ site of carcinogenesis; however, their roles are restricted to specific molecular subtypes. For example, in the majority of AML cases *MEIS1* and *HOXA9* act as oncogenes, while within a particular subtype of patients *MEIS1* and *HOXA9* expression are significantly decreased compared to other AML subtypes where such transcripts are over-represented.[@bib68] Patients with the AML-ETO fusion protein show low *MEIS1* and *HOXA9* mRNA as compared to other AML patients where high *MEIS1* expression are typical. *MEIS1* down regulation in the AML-ETO patient population is due to methylation at its promoter.[@bib68] Additionally, as described above, lung adenocarcinomas with LKB1 mutations display over-expression of MEIS whereas in NSCLC (non-small cell lung cancer) patients, MEIS1 over-expression inhibits cell growth and *MEIS1* knock down using siRNA-targeting increases proliferation.[@bib69] In this NSCLC context, DNA synthesis is increased when *MEIS1* decreased.[@bib69] Colorectal adenomas displayed a seven-fold decrease in *MEIS* transcripts, in particular a homeodomain-truncated splice-variant *MEIS1-D*.[@bib70], [@bib71] Thus, in numerous tumor types, *MEIS* expression appears to be actively inhibited, either via down-regulation or expression of dominant-negative splice variants.

MEIS and PBX proteins in prostate cancer {#sec11}
========================================

MEIS and PBX proteins have been vastly understudied in the context of prostate cancer, and there are numerous avenues of future investigation with clear clinical impact. MEIS1 has been shown to act as an androgen receptor suppressor, where ectopic expression slows LNCaP prostate cancer cell growth.[@bib72] MEIS1 can physically interact with the androgen receptor, the most critical driver of prostate cancer and the main target of clinical intervention.[@bib72], [@bib73], [@bib74] Moreover, work published by our group demonstrates that higher expression of *MEIS1* and *MEIS2* provide a survival benefit to men with intermediate and low-grade prostate cancer.[@bib73] In the normal prostate, MEIS expression is highest in basal epithelial cells and stromal cells, with a detectable but significantly lower expression in luminal epithelial cells. Tumors with below average *MEIS1* and *MEIS2* expression convey a significant decrease in patient survival, suggesting a functional role for decreased MEIS expression and the initiation and progression of poor-prognosis prostate tumors.[@bib73] Similarly, tumor expression of PBX3 was associated with improved prostate cancer specific survival compared to patients expressing low levels; this study statistically demonstrated that PBX3 expression could be used to potentially predict outcome and enhance tumor staging.[@bib75] However, significant additional work is required to more comprehensively understand the function of MEIS and other TALE proteins in prostate cancer.

Conclusions and future directions {#sec12}
=================================

Genetic and informatics studies in prostate cancer have clearly implicated a key role for MEIS/HOX signaling in prostate cancer initiation, and have created multiple avenues of potentially fruitful and impactful investigation. Based upon our understanding of MEIS/HOX function in other tumor types and our limited understanding in prostate cancer, several future research questions can be postulated. *First*, how does the *HOXB13(G84E)* mutation functionally lead to increased cancer initiation? It is important to elucidate when, during the development and maintenance of the prostate, the G84E mutation manifests itself; that is, to determine whether the prostate of a G84E carrier develops differently or does the G84E mutation impact prostate homeostasis and turnover after puberty and sexual maturity. *Second*, do other *HOXB13* mutations beyond G84E impact prostate function similarly or do they have unique etiologies and function? *Third*, how does the G84E mutation, and other *HOXB13* mutations, functionally modulate MEIS function and MEIS/HOX interactions? Mechanistic studies investigating whether the G84E mutation abrogates or modulates MEIS interaction, and the transcriptional impact of *HOXB13* mutations on *HOXB13* target genes, will illuminate how the G84E mutation leads to prostate tumor initiation. *Fourth and finally*, how can MEIS/HOX expression, and their gene targets, be exploited for patient benefit? Efforts to screen and genetically counsel individuals with *HOXB13* mutations are clearly warranted; however, mechanistic studies of MEIS/HOX transcriptional function has the high potential to identify targetable pathways for tumor prevention and staging.
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[^1]: a, b, c, d, e, f: Data from multiple populations present within a single study.

[^2]: h: Not reported.

[^3]: i: FB = Family Based; HB = Hospital Based; PB = Population Based.

[^4]: a, b, c, d, e: Data from multiple populations present within a single study.

[^5]: f: FB = Family Based; HB = Hospital Based; PB = Population Based.

[^6]: g: Unknown, mutation found in LAPC4 Cell Line.

[^7]: h: Unknown, mutation found in LNCaP Cell Line.
